GNPX
Price
$1.76
Change
-$0.05 (-2.76%)
Updated
Oct 27, 10:59 AM (EDT)
Capitalization
1.48M
17 days until earnings call
Intraday BUY SELL Signals
LNAI
Price
$0.25
Change
-$0.03 (-10.71%)
Updated
Oct 27, 11:04 AM (EDT)
Capitalization
1.25M
17 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GNPX vs LNAI

GNPX vs LNAI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GNPX vs. LNAI commentary
Oct 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a StrongBuy and LNAI is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for GNPX with price predictions
Oct 26, 2026

GNPX's Stochastic Oscillator stays in oversold zone for 21 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 148 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNPX as a result. In 67 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for GNPX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.100) is normal, around the industry mean (3.037). P/E Ratio (0.053) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LNAI with price predictions
Oct 26, 2026

LNAI's RSI Indicator sits in oversold zone for 20 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +9.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNAI advanced for three days, in 182 of 211 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

LNAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LNAI entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.131) is normal, around the industry mean (3.037). P/E Ratio (-0.004) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (294.118) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. LNAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LNAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
GNPX vs LNAI: Fundamental Ratings
GNPX
LNAI
OUTLOOK RATING
1..100
5869
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9798
P/E GROWTH RATING
1..100
955
SEASONALITY SCORE
1..100
3550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNPX's Valuation (49) in the Pharmaceuticals Major industry is in the same range as LNAI (53) in the Financial Conglomerates industry. This means that GNPX’s stock grew similarly to LNAI’s over the last 12 months.

GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LNAI (100) in the Financial Conglomerates industry. This means that GNPX’s stock grew similarly to LNAI’s over the last 12 months.

GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as LNAI (100) in the Financial Conglomerates industry. This means that GNPX’s stock grew similarly to LNAI’s over the last 12 months.

GNPX's Price Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as LNAI (98) in the Financial Conglomerates industry. This means that GNPX’s stock grew similarly to LNAI’s over the last 12 months.

LNAI's P/E Growth Rating (5) in the Financial Conglomerates industry is significantly better than the same rating for GNPX (95) in the Pharmaceuticals Major industry. This means that LNAI’s stock grew significantly faster than GNPX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNPXLNAI
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
76%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
COMPARISON
Comparison
Oct 27, 2026
Stock price -- (GNPX: $1.81 vs. LNAI: $0.28)
Brand notoriety: GNPX and LNAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNPX: 38% vs. LNAI: 340%
Market capitalization -- GNPX: $1.48M vs. LNAI: $1.25M
GNPX [@Biotechnology] is valued at $1.48M. LNAI’s [@Biotechnology] market capitalization is $1.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $131.16B. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNPX’s FA Score shows that 0 FA rating(s) are green while LNAI’s FA Score has 1 green FA rating(s).

  • GNPX’s FA Score: 0 green, 5 red.
  • LNAI’s FA Score: 1 green, 4 red.
According to our system of comparison, LNAI is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNPX’s TA Score shows that 4 TA indicator(s) are bullish while LNAI’s TA Score has 3 bullish TA indicator(s).

  • GNPX’s TA Score: 4 bullish, 3 bearish.
  • LNAI’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, both GNPX and LNAI are a good buy in the short-term.

Price Growth

GNPX (@Biotechnology) experienced а -12.14% price change this week, while LNAI (@Biotechnology) price change was -41.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -15.42%, and the average quarterly price growth was -14.11%.

Reported Earning Dates

GNPX is expected to report earnings on Nov 13, 2026.

LNAI is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GNPX
Daily Signal:
Gain/Loss:
LNAI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
N/A
CANF - GNPX
93%
Closely correlated
-3.37%
APVO - GNPX
86%
Closely correlated
-6.25%
ICU - GNPX
82%
Closely correlated
+2.49%
MLEC - GNPX
76%
Closely correlated
-11.63%
LONA - GNPX
76%
Closely correlated
-1.65%
More

LNAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, LNAI has been closely correlated with CANF. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if LNAI jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LNAI
1D Price
Change %
LNAI100%
-6.65%
CANF - LNAI
72%
Closely correlated
-3.37%
APVO - LNAI
60%
Loosely correlated
-6.25%
GNPX - LNAI
56%
Loosely correlated
N/A
ICU - LNAI
55%
Loosely correlated
+2.49%
MLEC - LNAI
48%
Loosely correlated
-11.63%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARW214.444.68
+2.23%
Arrow Electronics
ECPG99.641.91
+1.95%
Encore Capital Group
CBAN20.420.06
+0.29%
Colony Bankcorp Inc
TNON2.15-0.04
-2.05%
Tenon Medical Inc
ALIS8.04-0.60
-6.94%
Calisa Acquisition Corp